AIA Group Ltd Boosts Stock Holdings in Biogen Inc. $BIIB

AIA Group Ltd increased its stake in Biogen Inc. (NASDAQ:BIIB) by 310.1% during the 1st quarter, Holdings Channel reports. The fund owned 9,329 shares of the biotechnology company’s stock after purchasing an additional 7,054 shares during the quarter. AIA Group Ltd’s holdings in Biogen were worth $1,710,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rothschild Investment LLC grew its stake in Biogen by 12.3% during the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 56 shares in the last quarter. Kera Capital Partners Inc. raised its position in Biogen by 3.5% in the 1st quarter. Kera Capital Partners Inc. now owns 1,723 shares of the biotechnology company’s stock valued at $316,000 after purchasing an additional 58 shares in the last quarter. Itau Unibanco Holding S.A. boosted its stake in shares of Biogen by 24.4% in the 4th quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 66 shares during the period. Advisory Services Network LLC grew its position in shares of Biogen by 3.9% during the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after buying an additional 68 shares in the last quarter. Finally, Optas LLC increased its stake in shares of Biogen by 4.5% during the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock worth $300,000 after buying an additional 73 shares during the period. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen Stock Performance

Shares of BIIB stock opened at $205.99 on Monday. The stock’s 50-day moving average price is $199.43 and its 200 day moving average price is $189.09. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The stock has a market capitalization of $30.41 billion, a PE ratio of 22.10 and a beta of 0.16. Biogen Inc. has a 52-week low of $121.05 and a 52-week high of $219.72.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company’s revenue was up 1.9% on a year-over-year basis. During the same period last year, the business posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities research analysts forecast that Biogen Inc. will post 13.45 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on BIIB shares. Oppenheimer raised their target price on shares of Biogen from $275.00 to $300.00 and gave the company an “outperform” rating in a report on Thursday, May 14th. Mizuho dropped their price objective on shares of Biogen from $236.00 to $221.00 and set an “outperform” rating on the stock in a research report on Monday, June 15th. Sanford C. Bernstein reduced their price objective on shares of Biogen from $201.00 to $200.00 in a report on Thursday, April 30th. HC Wainwright restated a “buy” rating on shares of Biogen in a report on Thursday, May 14th. Finally, Citigroup lifted their price objective on shares of Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Biogen presently has an average rating of “Moderate Buy” and a consensus price target of $220.04.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.